Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
EBO-301 study to be discontinued following topline results from Phase 2 part of the study in treatment-refractory patients with MAC lung disease
AN2 plans to shift focus to internal boron chemistry platform and ongoing pipeline programs
Company restructuring and cost savings associated with discontinuation of the EBO-301 study expected to extend cash runway through 2027
Posted In: ANTX